Dongxu Zheng Qin

Dr. Dongxu Zheng Qin

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DQDongxu Zheng Qin
Dongxu Zheng Qin
ZYZheng Yongquan
Zheng Yongquan
LWLibo Wang
Libo Wang
ZLZhenyi Lin
Zhenyi Lin
YYYao Yao
Yao Yao
CZCaihong Zheng
Caihong Zheng
Endometriosis and Recurrent Implantation Failure (RIF) are both pivotal clinical issues within the realm of reproductive medicine, sharing significant overlap in their pathophysiological mechanisms. However, research exploring the commonalities between these two conditions remains relatively scarce, and reliable shared diagnostic biomarkers have yet to be identified. In this study, we integrated transcriptomic and single-cell sequencing data from the Gene Expression Omnibus (GEO) database to identify shared diagnostic genes and alterations in the cellular microenvironment between EMs and RIF. Differential expression analysis and weighted gene co-expression network analysis (WGCNA) were employed to identify key genes. Machine learning algorithms, including Random Forest (RF) and XGBoost, were utilized to screen for shared diagnostic genes, which were subsequently validated through receiver operating characteristic (ROC) analysis and clinical prediction models. Single-cell analysis was conducted to investigate the expression patterns of these diagnostic genes across various cellular subpopulations. Additionally, gene set enrichment analysis (GSEA) and competing endogenous RNA (ceRNA) network analysis were employed to further elucidate the biological functions and regulatory mechanisms of these genes. A total of 16 key genes were identified, which were predominantly expressed in fibroblasts. Through machine learning, the optimal model combining RF and XGBoost was selected to identify the shared diagnostic genes PDIA4 and PGBD5. Single-cell analysis revealed significant differences in the expression of these diagnostic genes in fibroblasts between normal and disease states. ROC analysis showed that the Area Under the Curve (AUC) values for individual genes in disease diagnosis were all above 0.7. The constructed clinical prediction model demonstrated robust predictive capacity for the disease. Immune infiltration analysis indicated that M2 macrophages and γδ T cells play important roles in the pathogenesis of EMs and RIF. GSEA revealed that these genes are involved in immune responses, vascular function, and hormone regulation, and are regulated by miR-3121-3p. This study provides comprehensive insights into the shared cellular microenvironmental alterations and molecular mechanisms underlying EMs and RIF. The identification of PDIA4 and PGBD5 as shared diagnostic biomarkers offers new avenues for early diagnosis and targeted treatment of EMs-related RIF. Future work will focus on validating these findings in larger cohorts and exploring their therapeutic potential.

3 January 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
XZXueZhi Zhao
XueZhi Zhao
ZYZheng Yongquan
Zheng Yongquan
XCXiaoyu Cai
Xiaoyu Cai
YYYao Yao
Yao Yao
DQDongxu Zheng Qin
Dongxu Zheng Qin
Non-coding RNAs have emerged as central regulators of gene expression in neurodegenerative diseases, offering new opportunities for diagnosis and therapy. This review synthesizes current knowledge on microRNAs, long non-coding RNAs, and circular RNAs in Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, emphasizing their roles in synaptic function, proteostasis, mitochondrial biology, and neuroinflammation. We evaluate evidence supporting non-coding RNAs as circulating and tissue-based biomarkers for early detection, disease monitoring, and patient stratification, and we compare analytical platforms and biofluid sources. Mechanistic insights reveal how non-coding RNAs modulate pathogenic protein aggregation, neuronal excitability, immune cell crosstalk, and blood–brain barrier integrity. Translational efforts toward RNA-targeted interventions are reviewed, including antisense oligonucleotides, small interfering RNAs, miRNA mimics and inhibitors, circular RNA decoys, and extracellular vesicle-mediated delivery systems. We discuss pharmacological modulation, delivery challenges, safety concerns, and strategies to enhance specificity and CNS penetration. Finally, we outline emerging computational and multi-omics approaches to prioritize therapeutic targets and propose a roadmap for advancing non-coding RNA research from preclinical models to clinical trials. Addressing biological heterogeneity and delivery barriers will be pivotal to realizing the diagnostic and therapeutic promise of the non-coding transcriptome in neurodegenerative disease. Collaboration across disciplines and rigorous clinical validation are urgently needed.

16 January 2026 in Medicine
Verified
Journal Article
Open access
ZYZheng Yongquan
Zheng Yongquan
DQDongxu Zheng Qin
Dongxu Zheng Qin
XZXiaoqian Zhang
Xiaoqian Zhang
HSHao Sun
Hao Sun
WFWeidong Fei
Weidong Fei
YYYao Yao
Yao Yao
Empirical investigations have identified associations between elevated branched-chain amino acids (BCAAs) levels and an increased incidence of hypertensive disorders of pregnancy (HDP). The aim of this study is to rigorously explore the causal linkage between BCAAs concentrations and the risk of developing HDP. A bidirectional Mendelian randomization (MR) analysis was conducted to ascertain the causal relationship between BCAAs levels and the risk of HDP. Instrumental genetic variables derived from the genome-wide association studies of serum BCAAs levels – encompassing total BCAAs, leucine, isoleucine and valine from the UK Biobank, and HDP data (16,417 cases and 213,893 controls) from the FinnGen consortium – were utilized. We conducted inverse-variance weighted, MR-Egger, simple mode, and weighted MR estimates. To assess the heterogeneity and potential presence of horizontal pleiotropy among the instrumental variables, Cochran Q statistic and the MR-Egger intercept were employed. Simultaneously, transcriptomic data were utilized in conjunction with machine learning to identify key genes through which BCAAs influence HDP. Single-cell techniques were employed to analyze the major cell populations. The forward MR analysis indicated a significant positive correlation between the levels of total BCAAs (OR: 1.300, 95% CI: 1.117–1.462; P < .0001), leucine (OR: 1.096, 95% CI: 1.123–1.505; P < .0001), and valine (OR: 1.299, 95% CI: 1.141–1.478; P < .0001) with the risk of HDP. Isoleucine levels (OR: 1.266, 95% CI: 1.054–1.521; P = .012) demonstrated a positive association with HDP risk that did not reach statistical significance after Bonferroni correction. The reverse analysis revealed no causal effect of HDP on the levels of total BCAAs (OR: 0.992, 95% CI: 0.967–1.018; P = .543), leucine (OR: 1.005, 95% CI: 0.973–1.039; P = .750), isoleucine (OR: 1.000, 95% CI: 0.974–1.026; P = .973), and valine (OR: 0.988, 95% CI: 0.962–1.014; P = .354). Transcriptomic analysis identified MCCC2 and BCAT2 as key genes through which BCAAs affect the occurrence of HDP, and these genes are predominantly expressed in endothelial cells. We provide robust evidence Our findings suggest that HDP was associated with an increased level of BCAAs, and the effects may be related to the expression levels of MCCC2 and BCAT2 in endothelial cells.